Fig. 2From: Novel 18-gene signature for predicting relapse in ER-positive, HER2-negative breast cancerConsolidated Standards of Reporting Trials (CONSORT) diagram of the availability of samples for analysis from (a) the ATAC trial and (b) the POLAR collection of samples. POLAR Molecular Predictors Of early versus LAte Recurrence in ER-positive breast cancer, ATACÂ Arimidex, Tamoxifen, Alone or in Combination, ER Oestrogen receptor, PgR Progesterone receptor, RMH Royal Marsden Hospital, LUH Lund University Hospital, ET Endocrine therapy, HER2 Human epidermal growth factor receptor 2Back to article page